Literature DB >> 22355469

Complete biologic response to taxane based chemotherapy confirmed by [F]FDG PET/CT and surgery in a cancer of unknown primary site.

Jun-Eul Hwang1, Ju-Young Yoon, Woo-Kyun Bae, Hyun-Jeong Shim, Ik-Joo Chung.   

Abstract

Cancers of an unknown primary site are heterogenous with respect to their clinical and pathologic features. They are generally very aggressive, but specific favorable subsets have a better prognosis. For these favorable subsets, taxane based chemotherapy is very effective for a subset of woman with papillary serous peritoneal adenocarcinoma. A 52 year-old woman underwent [(18)F]-FDG PET/CT for routine health screening. On PET/CT, multiple hypermetabolic lymph nodes were detected in the paraaortic spaces, and there were no other hypermetabolic abnormalities. The patient was diagnosed with an unknown primary cancer that probably originated from the ovary or peritoneum, according to clinical studies and biopsy results. This was not a typical case of a favorable subset of cancer of an unknown primary site, but the tumor showed complete biologic response to taxane based chemotherapy as revealed by PET/CT, and necrotic tumor cells were confirmed by surgery.

Entities:  

Keywords:  Chemotherapy; Positron emission tomography; Taxane; Unknown primary neoplasms

Year:  2012        PMID: 22355469      PMCID: PMC3280069          DOI: 10.3802/jgo.2012.23.1.65

Source DB:  PubMed          Journal:  J Gynecol Oncol        ISSN: 2005-0380            Impact factor:   4.401


  8 in total

Review 1.  Cancer of unknown primary: biological and clinical characteristics.

Authors:  N Pavlidis
Journal:  Ann Oncol       Date:  2003       Impact factor: 32.976

2.  Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer.

Authors:  Martin D Pickles; Peter Gibbs; Martin Lowry; Lindsay W Turnbull
Journal:  Magn Reson Imaging       Date:  2006-04-27       Impact factor: 2.546

3.  Introduction: unknown primary cancer.

Authors:  F Anthony Greco; John D Hainsworth
Journal:  Semin Oncol       Date:  2009-02       Impact factor: 4.929

Review 4.  Use of new imaging techniques to predict tumour response to therapy.

Authors:  Vanessa N Harry; Scott I Semple; David E Parkin; Fiona J Gilbert
Journal:  Lancet Oncol       Date:  2010-01       Impact factor: 41.316

5.  Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases.

Authors:  J C Dalrymple; P Bannatyne; P Russell; H J Solomon; M H Tattersall; K Atkinson; J Carter; P Duval; P Elliott; M Friedlander
Journal:  Cancer       Date:  1989-07-01       Impact factor: 6.860

6.  Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm.

Authors:  Jayne L Dennis; Torgeir R Hvidsten; Ernst C Wit; Jan Komorowski; Alexandra K Bell; Ian Downie; Jacqueline Mooney; Caroline Verbeke; Christopher Bellamy; W Nicol Keith; Karin A Oien
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

Review 7.  Treatment for patients with unknown primary cancer and favorable prognostic factors.

Authors:  John D Hainsworth; Karim Fizazi
Journal:  Semin Oncol       Date:  2009-02       Impact factor: 4.929

8.  Papillary serous carcinoma of the peritoneum.

Authors:  G L Fromm; D M Gershenson; E G Silva
Journal:  Obstet Gynecol       Date:  1990-01       Impact factor: 7.661

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.